Journal
ANNUAL REVIEW OF MEDICINE
Volume 61, Issue -, Pages 135-152Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev.med.60.042507.164323
Keywords
HIV vaccines; neutralizing antibodies; envelope glycoproteins; immunogenicity
Categories
Funding
- NIAID NIH HHS [AI074362, AI45378] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI045378, R01AI045378, R56AI074362, R01AI074362] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Developing an HIV-1 vaccine that can elicit antibodies to prevent infection has been a formidable challenge. Although no single immunogen has generated antibodies that can neutralize diverse isolates, progress has been made in understanding (a) the structure of the HIV-1 envelope glycoprotein, which is targeted by neutralizing antibodies, (b) how HIV-1 evades antibodies made by an infected host, and (c) how rare monoclonal antibodies can exhibit broadly neutralizing activity. Advances in structural and molecular biology coupled with new approaches to isolate neutralizing antibodies from HIV-1-infected individuals are enhancing our understanding of what humoral immune responses will be required for a vaccine. This review summarizes progress in understanding the host antibody response to HIV-1 and current strategies for applying this information to develop an effective vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available